Acadia Pharmaceuticals Inc. (ACAD)
Acadia Pharmaceuticals (ACAD) sees a surge in social media buzz and positive sentiment, driven by strong trial results for trofinetide and recent analyst upgrades. The stock is trading near a 52-week high, indicating significant investor interest.
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. is a healthcare company focused on treatments for neurological and related disorders.
Acadia Pharmaceuticals Inc. uses the ticker $ACAD for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Acadia Pharmaceuticals Inc. (ACAD) social dominance is up 345.83% from the previous week.
- Acadia Pharmaceuticals Inc. (ACAD) creators is up 169.44% from the previous week.
- Acadia Pharmaceuticals Inc. (ACAD) engagements is up 60.15% from the previous week.
- Acadia Pharmaceuticals Inc. (ACAD) mentions is up 123.19% from the previous week.
- Acadia Pharmaceuticals Inc. (ACAD) posts created is up 111.76% from the previous week.
Price: $22
Price 24-Hour Time-Series Raw Data
The stock is trading near a 52-week high, supported by positive trial results for trofinetide and recent analyst upgrades. The surge in social media activity and positive sentiment likely contributes to this upward trend, despite some short-term price volatility.
24-Hour: 0.64% 7-Day: -7.59% 30-Day: -15.24%
1-Year High: $28.10 on 2025-12-22
1-Year Low: $14.10 on 2025-04-08
AltRank: [-----]
AltRank 24-Hour Time-Series Raw Data
Acadia Pharmaceuticals Inc. (ACAD) is currently AltRank #1,082 based on combined combined social and market metrics
Daily Average: [-----]
[--] Week: [-----] [----]
[--] Month: [-----] [---]
[--] Months: [-----] +455
[--] Year: [-----] +401
1-Year High: [-----] on 2026-01-29
1-Year Low: [--] on 2025-12-20
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] no change
[--] Months: [--] [---]
[--] Year: [--] [---]
1-Year High: [--] on 2025-05-16
1-Year Low: [--] on 2025-06-01
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Week: [------] +60%
[--] Month: [------] -32%
[--] Months: [---------] -32%
[--] Year: [---------] +7.80%
1-Year High: [-------] on 2025-09-24
1-Year Low: [---] on 2025-05-03
Engagements by network (24h): X: [-----] TikTok: [--] Reddit: [--] YouTube: [---]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Week: [---] +123%
[--] Month: [---] +10%
[--] Months: [-----] -33%
[--] Year: [-----] +62%
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2026-01-25
Mentions by network (24h): X: [--] TikTok: [--] Reddit: [--] YouTube: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Acadia Pharmaceuticals Inc. (ACAD) in the last [--] hours which is down 13% from [--] in the previous [--] hours
Daily Average: [--]
[--] Week: [--] +169%
[--] Month: [---] +5.70%
[--] Months: [---] -49%
[--] Year: [-----] +105%
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2025-05-03
The most influential creators that mention Acadia Pharmaceuticals Inc. in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Hamnakedshorts | [--] | [-----] | [--] | [-----] |
| @BuyTheUgly | [--] | [--] | [--] | [---] |
| @Stock_Marketr11 | [--] | [---] | [--] | [--] |
Sentiment: 50%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 50%
Daily Average: 72%
[--] Week: 50% -17%
[--] Month: 60% -20%
[--] Months: 60% -28%
[--] Year: 60% -7%
1-Year High: 100% on 2025-04-23
1-Year Low: 23% on 2025-12-11
Most Supportive Themes:
- Positive Trial Results: (45%) Acadia Pharmaceuticals announced positive Phase [--] trial results for trofinetide in Rett syndrome.
- Analyst Upgrades and Strong Earnings: (30%) Strong earnings and analyst upgrades have driven ACAD to a 52-week high.
Most Critical Themes:
- Price Volatility: (10%) The stock has experienced price fluctuations, with a 24-hour change of -0.15% and varying performance over longer periods.
Social Dominance: 0.00241%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00241%
Daily Average: 0.013%
[--] Week: 0.011% +0.0083%
[--] Month: 0.0069% +0.0023%
[--] Months: 0.0069% -0.0056%
[--] Year: 0.0069% -0.012%
1-Year High: 0.044% on 2025-06-29
1-Year Low: 0.002% on 2026-01-25
Market Dominance: 0.00422%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00422%
Daily Average: 0%
1-Year High: 0.184% on 2026-02-06
1-Year Low: 0.00422% on 2026-02-16
Market Cap: $3,727,075,429
Market Cap 24-Hour Time-Series Raw Data
Current Value: $3,727,075,429
Daily Average: $3,713,738,752
[--] Week: $3,727,075,429 -5.10%
[--] Month: $3,727,075,429 -15%
[--] Months: $3,727,075,429 -11%
[--] Year: $3,727,075,429 +12%
1-Year High: $4,747,241,785 on 2025-12-22
1-Year Low: $2,351,718,090 on 2025-04-08
Top Acadia Pharmaceuticals Inc. Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"AC-262 Review by a Doctor💊 #bodybuilding #bodybuilder #shorts AC-262 sometimes hyped as the mild but effective option in the SARM family. 🔍 What is itAC-262 was developed by Acadia Pharmaceuticals and works by binding to androgen receptors in muscle and bone. Early animal data + user reports suggest: * ⚡ Moderate lean muscle gains * 💪 Fewer androgenic sides (compared to stronger SARMs) * 🔄 Still suppressive on natural testosterone (though less severe) ⚠ The catch * ❌ Very limited human research * 🧪 Mostly anecdotal and grey-market sourced * 🩺 Long-term safety Unknown 🧾 Reality check:"
YouTube Link @dralextatem 2025-08-26T20:26Z 80.9K followers, 22.7K engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing